Clinical Trial Update: Chemotherapy of NSCLC With or Without Icotinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating chemotherapy with vs without the EGFR inhibitor icotinib for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN